Pharmacotherapy of Diabetic Retinopathy

  • Toke Bek

Keywords: Ocular pharmacotherapy, aldose reductase inhibitors, PKC inhibitors, VEGF inhibitors, ACE inhibitors, somatostatin analogues, intravitreal steroids.


Diabetic Retinopathy Macular Edema Intravitreal Injection Aldose Reductase Diabetic Macular Edema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Michaelson JC. Retinal circulation in man and animals (Thomas, Springfield, Illinois, 1954) 1–146.Google Scholar
  2. 2.
    Sorbinil Retinopathy Trial Research Group. A randomozed trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108(9):1234–1244.Google Scholar
  3. 3.
    Tomlinson DR. Mitogen-activated protein kinases as glycose transducers for diabetic complications. Diabetologia 1999;42:1271–1281.CrossRefPubMedGoogle Scholar
  4. 4.
    Koya D and King GL. Protein Kinase C Activation and the development of diabetic complications. Diabetes 1998;47:859–866.CrossRefPubMedGoogle Scholar
  5. 5.
    Danis RP, Bingaman DP, Jirousek M et al. Inhibition of intraocular neovascularisation caused by retinal ischemia in pigs by af PKC β inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171–179.PubMedGoogle Scholar
  6. 6.
    Aiello LP. Medical and pharmacologic treatment of diabetic macular oedema. AAO Subspecialty Day, Anaheim CA, November 15, —vol. 18, 2003.Google Scholar
  7. 7.
    The PKC-DRS study group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188–2197.CrossRefGoogle Scholar
  8. 8.
    PKC-DRS2 Group. Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221–2230.CrossRefGoogle Scholar
  9. 9.
    Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102(4):647–661.Google Scholar
  10. 10.
    UKPD Study Group 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Brit M J 1998;317(7160):703–712.Google Scholar
  11. 11.
    Wilkinson-Berka JL. Diabetes and retinal vascular disorders: role of the rennin angiotensin system. Expert Rev Mol Med 2004;6:1–18.CrossRefPubMedGoogle Scholar
  12. 12.
    ETDRS Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS Report No 8. Ophthalmology 1991;98(5):757–765.Google Scholar
  13. 13.
    Poulsen J. The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 1953;2:7–1284, 722–733.Google Scholar
  14. 14.
    Baldysiak-Figiel A, Lang GK, Kampmeier J et al. Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrin. 2004;180:417–424.CrossRefGoogle Scholar
  15. 15.
    Boehm BO, Lang GK, Jehle PM et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Met Res. 2001;33: 300–306.CrossRefGoogle Scholar
  16. 16.
    Grant MB, Mames RN, Fitzgerald C et al. The efficacy of octreotide in the therapy of severe nonproliferative diabetic and early proliferative diabetic retinopathy. Diabetes Care 2000;23:504–509.CrossRefPubMedGoogle Scholar
  17. 17.
    Poulaki V, Joussen AM, Mitsiades N et al. Insulin-like growth factor-I plays a pathogenic role in diabetic retinopathy. Am J Pathol 2004;165:457–469.PubMedGoogle Scholar
  18. 18.
    Cunningham ET Jr, Adamis AO, Altaweel M et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer for diabetic macular edema. Ophthalmology 2005;112(10):1747–1757.CrossRefPubMedGoogle Scholar
  19. 19.
    Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant macular edema. Ophthalmology 2006;113(10):1706–1712.CrossRefPubMedGoogle Scholar
  20. 20.
    Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695–1705.e6.CrossRefPubMedGoogle Scholar
  21. 21.
    Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 2006;84(6):722–733.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Toke Bek
    • 1
  1. 1.Department of OphthalmologyAarhus University HospitalDenmark

Personalised recommendations